AU2016338540B2 - High-dose statins for age-related macular degeneration - Google Patents

High-dose statins for age-related macular degeneration Download PDF

Info

Publication number
AU2016338540B2
AU2016338540B2 AU2016338540A AU2016338540A AU2016338540B2 AU 2016338540 B2 AU2016338540 B2 AU 2016338540B2 AU 2016338540 A AU2016338540 A AU 2016338540A AU 2016338540 A AU2016338540 A AU 2016338540A AU 2016338540 B2 AU2016338540 B2 AU 2016338540B2
Authority
AU
Australia
Prior art keywords
patient
per day
amd
administration
dose statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016338540A
Other languages
English (en)
Other versions
AU2016338540A1 (en
Inventor
Joan W. Miller
Demetrios Vavvas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Publication of AU2016338540A1 publication Critical patent/AU2016338540A1/en
Application granted granted Critical
Publication of AU2016338540B2 publication Critical patent/AU2016338540B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2016338540A 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration Active AU2016338540B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241522P 2015-10-14 2015-10-14
US62/241,522 2015-10-14
PCT/US2016/056987 WO2017066529A1 (en) 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration

Publications (2)

Publication Number Publication Date
AU2016338540A1 AU2016338540A1 (en) 2018-05-24
AU2016338540B2 true AU2016338540B2 (en) 2022-04-28

Family

ID=58517927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016338540A Active AU2016338540B2 (en) 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration

Country Status (13)

Country Link
US (2) US11331295B2 (https=)
EP (1) EP3362063B1 (https=)
JP (3) JP7037186B2 (https=)
AU (1) AU2016338540B2 (https=)
CA (1) CA3001661C (https=)
DK (1) DK3362063T3 (https=)
ES (1) ES2941347T3 (https=)
FI (1) FI3362063T3 (https=)
IL (1) IL258604B2 (https=)
MX (1) MX391944B (https=)
PH (1) PH12018500745B1 (https=)
WO (1) WO2017066529A1 (https=)
ZA (1) ZA201803097B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11789024B2 (en) 2017-05-09 2023-10-17 Massachusetts Eye And Ear Infirmary Biomarkers for age-related macular degeneration
EP3654941A1 (en) * 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
WO2019079515A1 (en) * 2017-10-17 2019-04-25 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN-BASED TREATMENT IN AGE-RELATED MACULAR DEGENERATION (AMD)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
US20050250745A1 (en) * 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478317A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006083533A2 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
JP2008268506A (ja) * 2007-04-19 2008-11-06 Fuji Xerox Co Ltd 現像装置、像保持体ユニットおよび画像形成装置
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20120156202A1 (en) 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
EP3041479B1 (en) 2013-09-06 2023-04-26 Vanda Pharmaceuticals Inc. Treatment of cyr61- and vegf-mediated conditions
WO2016009430A1 (en) 2014-07-14 2016-01-21 Yeda Research And Development Co. Ltd Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
US20050250745A1 (en) * 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D T Q BARBOSA ET AL, EYE, GB, (2014-02-07), vol. 28, no. 4, doi:10.1038/eye.2014.8, ISSN 0950-222X, pages 472 - 480 *
ROBYN H. GUYMER ET AL, PLOS ONE, (2013-12-31), vol. 8, no. 12, doi:10.1371/journal.pone.0083759, page e83759 *

Also Published As

Publication number Publication date
ES2941347T3 (es) 2023-05-22
FI3362063T3 (fi) 2023-04-06
JP2022003042A (ja) 2022-01-11
EP3362063A4 (en) 2019-06-19
JP7754480B2 (ja) 2025-10-15
CA3001661C (en) 2025-05-06
IL258604A (en) 2018-06-28
US20210077457A1 (en) 2021-03-18
US20190209522A1 (en) 2019-07-11
IL258604B2 (en) 2024-09-01
MX2018004636A (es) 2019-06-20
IL258604B1 (en) 2024-05-01
DK3362063T3 (da) 2023-04-03
MX391944B (es) 2025-03-21
EP3362063A1 (en) 2018-08-22
US11331295B2 (en) 2022-05-17
EP3362063B1 (en) 2023-01-11
NZ742203A (en) 2025-06-27
US11744817B2 (en) 2023-09-05
PH12018500745B1 (en) 2023-03-15
JP2024016045A (ja) 2024-02-06
CA3001661A1 (en) 2017-04-20
ZA201803097B (en) 2022-12-21
JP7037186B2 (ja) 2022-03-16
JP2018530586A (ja) 2018-10-18
PH12018500745A1 (en) 2018-10-15
WO2017066529A1 (en) 2017-04-20
AU2016338540A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
Chaudhuri et al. Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness
JP2024016045A (ja) 加齢黄斑変性のための高用量スタチン
Holz et al. Geographic atrophy: clinical features and potential therapeutic approaches
US20200316066A1 (en) Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
JP2014515408A (ja) 行動及び精神障害の治療のためのシロ−イノシトール
US11123412B2 (en) Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
KR20080018874A (ko) 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법
Shome et al. Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration
EP2994197B1 (en) Pharmaceutical combination of an nsaid and atropine
Liu et al. Bone marrow mesenchymal stem cells enhance autophagy and help protect cells under hypoxic and retinal detachment conditions
JP6873504B2 (ja) アルツハイマー病の治療及び／又は予防のための組成物
US20260048083A1 (en) Method of treating alzheimer's disease with expanded natural killer cells
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
Chen et al. Vitamin K1 alleviates retinal inflammation following acute ocular hypertension by modulating microglial ferroptosis
Jain Neuroprotection in Alzheimer disease
US11096993B2 (en) Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
Falkon Endo/Lysosomal Uptake and Degradation of Protein Aggregates in Tauopathy
Olchawa The effect of oxidative stress on phagocytic activity of retinal pigment epithelium cells in vitro
Heale Alterations in autophagy marker distribution in different genetic subtypes of frontotemporal lobar degeneration
WO2023004044A2 (en) Compositions and methods for treating neurodegenerative diseases by inhibiting fsh
CN101287370A (zh) 用于增强与人类疾病相关的突变蛋白质的降解的物质与方法
HK40080196A (en) Biomolecule for treatment of corneal pathologies
EP3648794A1 (en) Use of macroazapyridinophanes metal complexes in the treatment of diseases
Haugsdal et al. Ophthalmology and Visual Sciences
JP2017132742A (ja) Ａβオリゴマー特異的抗体の新規薬理用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)